

WHAT IS CLAIMED IS:

Sub B3

1. A high-throughput method of screening compounds capable of modulating topoisomerase activity comprising:
 - (a) incubating at least a first nucleic acid, a topoisomerase and a potential topoisomerase-modulating compound, wherein the nucleic acid comprises at least one tag, and
 - (b) assaying for nucleic acid religation.
2. The method of claim 1, wherein the nucleic acid is DNA.
3. The method of claim 1, wherein the nucleic acid is RNA.
4. The method of claim 1, wherein the at least one tag is a detection tag or an affinity tag.
5. The method of claim 1, wherein the method comprises incubating at least a first nucleic acid and a second nucleic acid.
6. The method of claim 5, wherein the second nucleic acid is a religation strand comprising oligonucleotides operatively associated with at least one marker tag.
7. The method of claim 6, wherein the first nucleic acid is operatively associated with an affinity tag and the second nucleic acid is operatively associated with a detection tag.
8. The method of claim 1, wherein the assay detects for topoisomerase inhibitors

0958342.053100

9. The method of claim 1, wherein the assay detects for topoisomerase activators.

10. The method of claim 1, wherein the topoisomerase is a Type I or Type III topoisomerase.

11. The method of claim 1, wherein the topoisomerase is a Type II or Type IV topoisomerase.

12. The method of claim 1, wherein assaying comprises measuring the level of nucleic acid religation activity in the presence and absence of the topoisomerase-modulating compound

13. The method of claim 1, wherein the level of religation activity is inversely proportional to the effectiveness of the topoisomerase-inhibitory compound.

14. The method of claim 1, wherein step (a) is performed on a solid support.

15. The method of claim 1, wherein step (a) is performed in a liquid phase.

16. The method of claim 1, wherein the nucleic acid and topoisomerase are covalently complexed, wherein the topoisomerase retains its religation activity.

17. A method of treating cancer comprising administering a pharmaceutical composition comprising a topoisomerase inhibitor to a patient in need thereof.

18. A method of treating an infection by a pathogen comprising administering a pharmaceutical composition comprising a topoisomerase inhibitor to a patient in need thereof.

19. The method of claim 18, wherein the ~~the~~ pathogen is a virus, bacterium, fungus or parasite.

Sub B4
20. A kit for screening compounds that modulate topoisomerase religation activity comprising:

- (a) a substrate nucleic acid comprising a first tag,
- (b) a religation nucleic acid comprising a second tag,
- (c) a topoisomerase, and
- (d) a means for measuring nucleic acid religation activity of a test mixture comprising (a), (b) and (c) in the presence or absence of a topoisomerase-modulating compound.

21. A high-throughput method of screening compounds capable of modulating nucleic acid-modifying enzymatic activity comprising:

- (a) incubating at least a first nucleic acid, a nucleic acid-modifying enzyme and a potential enzyme-modulating compound, wherein the nucleic acid comprises at least one tag, and
 - (b) assaying for nucleic acid religation or cleavage.
- Add B5